Home  /  Resource Library  /  The ECHELON-2 Trial: 5 Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30 Positive Peripheral T-Cell Lymphoma

The ECHELON-2 Trial: 5 Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30 Positive Peripheral T-Cell Lymphoma

SOHO 2021: Long term results of a study investigating brentuximab Vedotin combined with chemotherapy for treatment of peripheral T-cell lymphomas. (Abstract only)